Subscribe
Sign in
Share this post
The Drug Development Letter
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
Copy link
Facebook
Email
Notes
More
Tislelizumab, a novel anti-PD1 in…
Timothée Olivier
Sep 8
17
Share this post
The Drug Development Letter
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
Copy link
Facebook
Email
Notes
More
1
Quality-of-life data should be interpreted with extra caution when censoring rates are high.
Read →
Comments
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
Share this post
Tislelizumab, a novel anti-PD1 in…
Share this post
Quality-of-life data should be interpreted with extra caution when censoring rates are high.